About ela-dev

This author has not yet filled in any details.
So far ela-dev has created 8 blog entries.

Cadent Therapeutics to Present at the Jefferies Healthcare Conference

By |2019-05-30T14:39:03+00:00May 28th, 2019|

Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement and cognitive disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the Jefferies Healthcare Conference on Tuesday, June 4, 2019 at 10:00 am ET in New York City.

Cadent Therapeutics Receives Milestone Payment for Initiation of Phase 2 Trial of MIJ821 in Treatment-Resistant Depression

By |2019-05-30T14:40:53+00:00May 23rd, 2019|

Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement and cognitive disorders, today announced the receipt of the second milestone payment from Novartis following the initiation of a Phase 2 clinical study of MIJ821, a subtype selective NMDA receptor negative allosteric modulator (NAM), in development for treatment-resistant depression (TRD).

Cadent Therapeutics Appoints Jodie Morrison as Chief Executive Officer

By |2019-02-14T11:55:48+00:00February 14th, 2019|

Cadent Therapeutics, a company focused on the development of breakthrough therapies to improve the lives of patients with movement and neurological disorders, today announced that Jodie Morrison has been appointed Chief Executive Officer and has also joined Cadent’s Board of Directors. Ms. Morrison brings to Cadent more than 20 years of executive leadership...

Cadent Therapeutics Secures $40 Million Series B Financing to Advance Pipeline of Novel Therapies for Movement and Cognitive Disorders

By |2018-11-15T13:22:07+00:00November 15th, 2018|

Cadent Therapeutics, a company focused on the development of breakthrough therapies to improve the lives of patients with movement and cognitive disorders, today announced that it has raised $40 million in a Series B financing. In addition, the company has appointed Bob (Ibrahim) Dagher, M.D., as Chief Medical Officer.

Cadent Therapeutics Initiates Phase 1 Study of Lead Compound CAD-1883

By |2018-11-08T22:47:16+00:00March 12th, 2018|

Cadent Therapeutics, a precision neuroscience company developing novel medicines to restore movement and cognitive function in patients with neurological and psychiatric disease, today announced the initiation of a Phase 1 clinical study for its lead product candidate CAD-1883. The compound is a selective first-in-class positive allosteric modulator of the small conductance calcium-activated potassium (SK) channel.